Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Rheumatology Reviews
  4. Volume 21, Issue 1
  5. Article
Volume 21, Issue 1
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Objective

To provide evidence-based clinical practice recommendations for managing Systemic Lupus Erythematosus (SLE) in Saudi Arabia.

Methods

This EULAR-adapted national guideline in which a multidisciplinary task force utilized the modified Delphi method to develop 31 clinical key questions. A systematic literature review was conducted to update the evidence since the EULAR publication. After reaching a consensus agreement, two rounds of voting and group discussion were conducted to generate consolidated recommendations/statements.

Results

A significant number of patients in Saudi Arabia experience delays in accessing rheumatologists, highlighting the significance of timely referral to SLE specialists or rheumatologists to ensure accurate diagnosis and prompt treatment. The primary goal of Glucocorticoid (GC) therapy in SLE patients is to establish disease control with a minimum dose and duration. Steroid-sparing agent utilization facilitates steroid-sparing goals. Hydroxychloroquine is recommended for all SLE patients, though physicians must carefully monitor toxicity and prioritize regular medication adherence assessment. SLE management during pregnancy starts from preconception time by assessing disease activity, major organ involvement, hypercoagulability status, and concomitant diseases that may negatively impact maternal and fetal outcomes. Multidisciplinary care with close monitoring may optimize both maternal and fetal outcomes. For patients with antiphospholipid antibodies, low-dose aspirin prophylaxis is recommended. Also, Long-term anticoagulant medications are fundamental to prevent secondary antiphospholipid syndrome due to high thrombosis recurrence.

Conclusion

This Saudi National Clinical Practice guidelines for SLE management provide evidence-based recommendations and guidance for healthcare providers in Saudi Arabia who are managing patients with SLE. These guidelines will help to standardize healthcare service, improve provider education, and perhaps lead to better treatment outcomes for SLE patients.

© 2025 Bentham Science Publishers
© 2025 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971275638240429063041
2024-04-30
2025-05-21

  • From This Site

    /content/journals/crr/10.2174/0115733971275638240429063041
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. D’CruzD.P. KhamashtaM.A. HughesG.R.V. Systemic lupus erythematosus.Lancet2007369956158759610.1016/S0140‑6736(07)60279‑717307106
     [Google Scholar]
  2. BoumpasD.T. AustinH.A.III FesslerB.J. BalowJ.E. KlippelJ.H. LockshinM.D. Systemic lupus erythematosus: Emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease.Ann. Intern. Med.19951221294095010.7326/0003‑4819‑122‑12‑199506150‑000097755231
     [Google Scholar]
  3. CojocaruM. CojocaruI.M. SilosiI. VrabieC.D. Manifestations of systemic lupus erythematosus.Maedica20116433033622879850
     [Google Scholar]
  4. Al-ArfajA.S. Al-BallaS.R. Al-DalaanA.N. Al-SalehS.S. BahabriS.A. MousaM.M. SekeitM.A. Prevalence of systemic lupus erythematosus in central Saudi Arabia.Saudi Med. J.2002231878911938371
     [Google Scholar]
  5. HassenL.M. AlbarrakR.A. AlbahlalR.A. AlsaqabiD.K. HassenI.M. DaghestaniM.H. AlqurtasE.M. AlkhalafA.T. BedaiwiM.K. OmairM.A. AlmaghlouthI.A. Functional and psychosocial impact of COVID-19 pandemic on rheumatic patients’ quality of life in Saudi Arabia.Qual. Life Res.202231113229323910.1007/s11136‑022‑03184‑135857205
     [Google Scholar]
  6. DougadosM. BetteridgeN. BurmesterG.R. Euller-ZieglerL. GuilleminF. HirvonenJ. LloydJ. OzenS. Da SilvaJ.A. EmeryP. KaldenJ.R. KvienT. Matucci-CerinicM. SmolenJ. EULAR EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees.Ann. Rheum. Dis.20046391172117610.1136/ard.2004.02369715308532
     [Google Scholar]
  7. FanouriakisA. KostopoulouM. AlunnoA. AringerM. BajemaI. BoletisJ.N. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus.Ann Rheum Dis2019786736745
     [Google Scholar]
  8. BrouwersM.C. KhoM.E. BrowmanG.P. BurgersJ.S. CluzeauF. FederG. FerversB. GrahamI.D. GrimshawJ. HannaS.E. LittlejohnsP. MakarskiJ. ZitzelsbergerL. AGREE Next Steps Consortium AGREE II: Advancing guideline development, reporting and evaluation in health care.CMAJ201018218E839E84210.1503/cmaj.09044920603348
     [Google Scholar]
  9. DengJ. ChalhoubN.E. SherwinC.M. LiC. BrunnerH.I. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus.Semin. Arthritis Rheum.201949225125910.1016/j.semarthrit.2019.03.01030987856
     [Google Scholar]
  10. RhenT. CidlowskiJ.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs.N. Engl. J. Med.2005353161711172310.1056/NEJMra05054116236742
     [Google Scholar]
  11. AdamiG. SaagK.G. Glucocorticoid-induced osteoporosis: 2019 concise clinical review.Osteoporos. Int.20193061145115610.1007/s00198‑019‑04906‑x30805679
     [Google Scholar]
  12. Rúa-FigueroaI. López-LongoF.J. Del CampoV. Galindo-IzquierdoM. UriarteE. Torre-CisnerosJ. VelaP. TomeroE. NarváezJ. OlivéA. FreireM. SalgadoE. AndreuJ.L. Martínez-TaboadaV. Calvo-AlénJ. Hernández-CruzB. RayaE. QuevedoV. Expósito PérezL. Fernández-NebroA. IbañezM. Pascual-VallsÈ. Rúa-FigueroaD. NaranjoA. Pego-ReigosaJ.M. Bacteremia in systemic lupus erythematosus in patients from a spanish registry: Risk factors, clinical and microbiological characteristics, and outcomes.J. Rheumatol.202047223424010.3899/jrheum.18088230988123
     [Google Scholar]
  13. Pimentel-QuirozV.R. Ugarte-GilM.F. HarveyG.B. WojdylaD. Pons-EstelG.J. QuintanaR. EspostoA. GarcíaM.A. CatoggioL.J. CardielM.H. BarileL.A. AmigoM.C. SatoE.I. BonfaE. BorbaE. Lavras CostallatL.T. NeiraO.J. MassardoL. Guibert-ToledanoM. Chacón-DíazR. AlarcónG.S. Pons-EstelB.A. Factors predictive of serious infections over time in systemic lupus erythematosus patients: Data from a multi-ethnic, multi-national, Latin American lupus cohort.Lupus20192891101111010.1177/096120331986057931291843
     [Google Scholar]
  14. Mejía-ViletJM AyoubI The use of glucocorticoids in lupus nephritis: New pathways for an old drug.Front Med20218622225
     [Google Scholar]
  15. UrowitzM.B. GladmanD.D. IbañezD. SuJ. MursleenS. SayaniA. Ross TerresJ.A. IczkovitzS. Effect of disease activity on organ damage progression in systemic lupus erythematosus: University of toronto lupus clinic cohort.J. Rheumatol.2021481677310.3899/jrheum.19025932238510
     [Google Scholar]
  16. ButtgereitF. da SilvaJ.A. BoersM. BurmesterG.R. CutoloM. JacobsJ. KirwanJ. KöhlerL. Van RielP. VischerT. BijlsmaJ.W. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology.Ann. Rheum. Dis.200261871872210.1136/ard.61.8.71812117678
     [Google Scholar]
  17. SinghJ.A. HossainA. KotbA. WellsG. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: A systematic review and network meta-analysis.BMC Med.201614113710.1186/s12916‑016‑0673‑827623861
     [Google Scholar]
  18. Pons-EstelB.A. BonfaE. SorianoE.R. CardielM.H. IzcovichA. PopoffF. CrinitiJ.M. VásquezG. MassardoL. DuarteM. Barile-FabrisL.A. GarcíaM.A. AmigoM.C. EspadaG. CatoggioL.J. SatoE.I. LevyR.A. Acevedo VásquezE.M. Chacón-DíazR. Galarza-MaldonadoC.M. Iglesias GamarraA.J. MolinaJ.F. NeiraO. SilvaC.A. Vargas PeñaA. Gómez-PuertaJ.A. ScolnikM. Pons-EstelG.J. Ugolini-LopesM.R. SavioV. DrenkardC. AlvarellosA.J. Ugarte-GilM.F. BabiniA. CavalcantiA. Cardoso LinharesF.A. Haye SalinasM.J. Fuentes-SilvaY.J. Montandon de Oliveira e SilvaA.C. Eraso GarnicaR.M. Herrera UribeS. Gómez-MartínD. Robaina SevriniR. QuintanaR.M. GordonS. Fragoso-LoyoH. RosarioV. SauritV. AppenzellerS. dos Reis NetoE.T. CiezaJ. González NaranjoL.A. González BelloY.C. ColladoM.V. SaranoJ. RetamozoS. SattlerM.E. Gamboa-CárdenasR.V. CairoliE. ContiS.M. Amezcua-GuerraL.M. SilveiraL.H. BorbaE.F. PeraM.A. Alba MoreyraP.B. ArturiV. BerbottoG.A. GerlingC. GobbiC.A. GervasoniV.L. ScherbarthH.R. BrenolJ.C.T. CavalcantiF. CostallatL.T.L. Da SilvaN.A. MonticieloO.A. SeguroL.P.C. XavierR.M. LlanosC. Montúfar GuardadoR.A. Garcia de la TorreI. PinedaC. Portela HernándezM. DanzaA. Guibert-ToledanoM. ReyesG.L. Acosta ColmanM.I. AquinoA.M. Mora-TrujilloC.S. Muñoz-LouisR. García ValladaresI. OrozcoM.C. BurgosP.I. BetancurG.V. AlarcónG.S. Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR) First latin american clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin american group for the study of lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-american league of associations of rheumatology (PANLAR).Ann. Rheum. Dis.201877111549155710.1136/annrheumdis‑2018‑21351230045853
     [Google Scholar]
  19. Ruiz-IrastorzaG EspinosaG FrutosMA Jiménez AlonsoJ PragaM PallarésL Diagnosis and treatment of lupus nephritis.Span. Clin. Mag.2012212314710.1016/j.rce.2012.01.001
     [Google Scholar]
  20. BruceI.N. O’KeeffeA.G. FarewellV. HanlyJ.G. ManziS. SuL. GladmanD.D. BaeS.C. Sanchez-GuerreroJ. Romero-DiazJ. GordonC. WallaceD.J. ClarkeA.E. BernatskyS. GinzlerE.M. IsenbergD.A. RahmanA. MerrillJ.T. AlarcónG.S. FesslerB.J. FortinP.R. PetriM. SteinssonK. DooleyM.A. KhamashtaM.A. Ramsey-GoldmanR. ZomaA.A. SturfeltG.K. NivedO. AranowC. MackayM. Ramos-CasalsM. van VollenhovenR.F. KalunianK.C. Ruiz-IrastorzaG. LimS. KamenD.L. PeschkenC.A. InancM. UrowitzM.B. Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the systemic lupus international collaborating clinics (SLICC) inception cohort.Ann. Rheum. Dis.20157491706171310.1136/annrheumdis‑2013‑20517124834926
     [Google Scholar]
  21. ChenH.L. ShenL.J. HsuP.N. ShenC.Y. HallS.A. HsiaoF.Y. Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: Findings from a 12-year longitudinal study.J. Rheumatol.2018451838910.3899/jrheum.16021429142034
     [Google Scholar]
  22. LimL.S.H. PullenayegumE. LimL. GladmanD. FeldmanB. SilvermanE. From childhood to adulthood: The trajectory of damage in patients with juvenile-onset systemic lupus erythematosus.Arthritis Care Res.201769111627163510.1002/acr.2319928118527
     [Google Scholar]
  23. AbeK. IshikawaY. KitaY. YajimaN. InoueE. SadaK. MiyawakiY. YoshimiR. ShimojimaY. OhnoS. KajiyamaH. IchinoseK. SatoS. FujiwaraM. Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: A prospective cohort study.Arthritis Res. Ther.202224117910.1186/s13075‑022‑02869‑935902976
     [Google Scholar]
  24. van VollenhovenR. VoskuylA. BertsiasG. AranowC. AringerM. ArnaudL. AskanaseA. BalážováP. BonfaE. BootsmaH. BoumpasD. BruceI. CerveraR. ClarkeA. ConeyC. Costedoat-ChalumeauN. CzirjákL. DerksenR. DoriaA. DörnerT. Fischer-BetzR. Fritsch-StorkR. GordonC. GraningerW. GyöriN. HoussiauF. IsenbergD. JacobsenS. JayneD. KuhnA. Le GuernV. LerstrømK. LevyR. Machado-RibeiroF. MarietteX. MissaykehJ. MorandE. MoscaM. InancM. NavarraS. NeumannI. OlesinskaM. PetriM. RahmanA. RekvigO.P. RovenskyJ. ShoenfeldY. SmolenJ. TincaniA. UrowitzM. van LeeuwB. VasconcelosC. VossA. WerthV.P. ZakharovaH. ZomaA. SchneiderM. WardM. A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS).Ann. Rheum. Dis.201776355456110.1136/annrheumdis‑2016‑20951927884822
     [Google Scholar]
  25. FranklynK. LauC.S. NavarraS.V. LouthrenooW. LateefA. HamijoyoL. WahonoC.S. ChenS.L. JinO. MortonS. HoiA. HuqM. NikpourM. MorandE.F. Asia-Pacific Lupus Collaboration Definition and initial validation of a lupus low disease activity state (LLDAS).Ann. Rheum. Dis.20167591615162110.1136/annrheumdis‑2015‑20772626458737
     [Google Scholar]
  26. NakaiT. FukuiS. IkedaY. SudaM. TamakiH. OkadaM. Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: A single-center retrospective analysis.Lupus Sci. Med.202291e00068210.1136/lupus‑2022‑00068235654482
     [Google Scholar]
  27. TaniC. ElefanteE. SignoriniV. ZucchiD. LorenzoniV. CarliL. StagnaroC. FerroF. MoscaM. Glucocorticoid withdrawal in systemic lupus erythematosus: Are remission and low disease activity reliable starting points for stopping treatment? A real-life experience.RMD Open201952e00091610.1136/rmdopen‑2019‑00091631275608
     [Google Scholar]
  28. TseliosK. GladmanD.D. SuJ. UrowitzM.B. Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus.ACR Open Rheumatol.20213855055710.1002/acr2.1126734245233
     [Google Scholar]
  29. BelmontH.M. Treatment of systemic lupus erythematosus - 2013 update.Bull. Hosp. Jt. Dis.201371320821324151947
     [Google Scholar]
  30. Ruiz-IrastorzaG. Ramos-CasalsM. Brito-ZeronP. KhamashtaM.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review.Ann. Rheum. Dis.2010691202810.1136/ard.2008.10176619103632
     [Google Scholar]
  31. Almeida-BrasilC.C. HanlyJ.G. UrowitzM. ClarkeA.E. Ruiz-IrastorzaG. GordonC. Ramsey-GoldmanR. PetriM. GinzlerE.M. WallaceD.J. BaeS.C. Romero-DiazJ. DooleyM.A. PeschkenC. IsenbergD. RahmanA. ManziS. JacobsenS. LimS. van VollenhovenR.F. NivedO. JönsenA. KamenD.L. AranowC. Sanchez-GuerreroJ. GladmanD.D. FortinP.R. AlarcónG.S. MerrillJ.T. KalunianK. Ramos-CasalsM. SteinssonK. ZomaA. AskanaseA. KhamashtaM.A. BruceI.N. InancM. AbrahamowiczM. BernatskyS. Flares after hydroxychloroquine reduction or discontinuation: Results from the systemic lupus international collaborating clinics (SLICC) inception cohort.Ann. Rheum. Dis.202281337037810.1136/annrheumdis‑2021‑22129534911705
     [Google Scholar]
  32. MeinãoI.M. SatoE.I. AndradeL. FerrazM.B. AtraE. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus.Lupus19965323724110.1177/0961203396005003138803897
     [Google Scholar]
  33. GroupC.H.S. Canadian Hydroxychloroquine Study Group A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.N. Engl. J. Med.1991324315015410.1056/NEJM1991011732403031984192
     [Google Scholar]
  34. AkhavanP.S. SuJ. LouW. GladmanD.D. UrowitzM.B. FortinP.R. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.J. Rheumatol.201340683184110.3899/jrheum.12057223588942
     [Google Scholar]
  35. Pons-EstelG.J. AlarcónG.S. GonzálezL.A. ZhangJ. ViláL.M. ReveilleJ.D. McGwinG.Jr Lumina Study Group Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort.Arthritis Care Res.201062339340010.1002/acr.2009720391486
     [Google Scholar]
  36. JungH. BobbaR. SuJ. Shariati-SarabiZ. GladmanD.D. UrowitzM. LouW. FortinP.R. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.Arthritis Rheum.201062386386810.1002/art.2728920131232
     [Google Scholar]
  37. MokC.C. PennH.J. ChanK.L. TseS.M. LangmanL.J. JannettoP.J. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: A longitudinal cohort analysis.Arthritis Care Res.20166891295130210.1002/acr.2283726749299
     [Google Scholar]
  38. IudiciM. PantanoI. FasanoS. PierroL. CharlierB. PingeonM. Dal PiazF. FilippelliA. IzzoV. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.Lupus201827226527210.1177/096120331771763128659047
     [Google Scholar]
  39. Costedoat-ChalumeauN. AmouraZ. HulotJ.S. AymardG. LerouxG. MarraD. LechatP. PietteJ.C. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.Ann. Rheum. Dis.200766682182410.1136/ard.2006.06783517324970
     [Google Scholar]
  40. MellesR.B. MarmorM.F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.JAMA Ophthalmol.2014132121453146010.1001/jamaophthalmol.2014.345925275721
     [Google Scholar]
  41. KimJ.W. KimY.Y. LeeH. ParkS.H. KimS.K. ChoeJ.Y. Risk of retinal toxicity in longterm users of hydroxychloroquine.J. Rheumatol.201744111674167910.3899/jrheum.17015828864645
     [Google Scholar]
  42. MarmorM.F. KellnerU. LaiT.Y.Y. MellesR.B. MielerW.F. American Academy of Ophthalmology Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision).Ophthalmology201612361386139410.1016/j.ophtha.2016.01.05826992838
     [Google Scholar]
  43. FasanoS. MessinitiV. IudiciM. CosciaM.A. CicciaF. Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.Lupus Sci. Med.2023101e00084110.1136/lupus‑2022‑00084136631164
     [Google Scholar]
  44. Vázquez-OteroI. Medina-CintrónN. Arroyo-ÁvilaM. González-SepúlvedaL. ViláL.M. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.Lupus Sci. Med.202071e00039510.1136/lupus‑2020‑00039532434863
     [Google Scholar]
  45. BahloulE. JallouliM. GarbaaS. MarzoukS. MasmoudiA. TurkiH. BahloulZ. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: Prevalence, clinical features and risk factors: A cross-sectional study of 41 cases.Lupus201726121304130810.1177/096120331770048628355984
     [Google Scholar]
  46. JallouliM. FrancèsC. PietteJ.C. HuongL.T. MogueletP. FactorC. ZahrN. MiyaraM. SaadounD. MathianA. HarocheJ. De GennesC. LerouxG. ChapelonC. WechslerB. CacoubP. AmouraZ. Costedoat-ChalumeauN. Plaquenil LUpus Systemic Study Group Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: A case-control study.JAMA Dermatol.2013149893594010.1001/jamadermatol.2013.70923824340
     [Google Scholar]
  47. Pego-ReigosaJ.M. Cobo-IbáñezT. Calvo-AlénJ. Loza-SantamaríaE. RahmanA. Muñoz-FernándezS. Rúa-FigueroaÍ. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: A systematic review.Arthritis Care Res.201365111775178510.1002/acr.2203523609987
     [Google Scholar]
  48. SakthiswaryR. SureshE. Methotrexate in systemic lupus erythematosus: A systematic review of its efficacy.Lupus201423322523510.1177/096120331351915924399812
     [Google Scholar]
  49. SztejnbokM. StewartA. DiamondH. KaplanD. Azathioprine in the treatment of systemic lupus erythematosus. A controlled study.Arthritis Rheum.197114563964510.1002/art.17801405114106177
     [Google Scholar]
  50. GinzlerE. SharonE. DiamondH. KaplanD. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus.Arthritis Rheum.1975181273410.1002/art.17801801061115745
     [Google Scholar]
  51. GrootscholtenC. LigtenbergG. HagenE.C. van den Wall BakeA.W.L. de Glas-VosJ.W. BijlM. AssmannK.J. BruijnJ.A. WeeningJ.J. van HouwelingenH.C. DerksenR.H.W.M. BerdenJ.H.M. Dutch Working Party on Systemic Lupus Erythematosus Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.Kidney Int.200670473274210.1038/sj.ki.500163016820790
     [Google Scholar]
  52. HoussiauF.A. D’CruzD. SangleS. RemyP. VasconcelosC. PetrovicR. FiehnC. de Ramon GarridoE. GilboeI.M. TektonidouM. BlockmansD. RavelingienI. le GuernV. DepresseuxG. GuillevinL. CerveraR. MAINTAIN Nephritis Trial Group Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN nephritis trial.Ann. Rheum. Dis.201069122083208910.1136/ard.2010.13199520833738
     [Google Scholar]
  53. GriffithsB. EmeryP. RyanV. IsenbergD. AkilM. ThompsonR. MaddisonP. GriffithsI.D. LorenziA. MilesS. SitunayakeD. TehL.S. PlantM. HallengrenC. NivedO. SturfeltG. ChakravartyK. TaitT. GordonC. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.Rheumatology201049472373210.1093/rheumatology/kep39620081225
     [Google Scholar]
  54. MokC.C. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: A systematic review.Scand. J. Rheumatol.200736532933710.1080/0300974070160704217963161
     [Google Scholar]
  55. GinzlerE.M. WofsyD. IsenbergD. GordonC. LiskL. DooleyM.A. ALMS Group Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.Arthritis Rheum.201062121122110.1002/art.2505220039429
     [Google Scholar]
  56. TseliosK. GladmanD.D. SuJ. UrowitzM.B. Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: An observational cohort study.J. Rheumatol.201643355255810.3899/jrheum.15077926773121
     [Google Scholar]
  57. GardinerK.M. TettS.E. StaatzC.E. Is conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium justifiable for gastrointestinal quality of life?Drugs R D.201818427128210.1007/s40268‑018‑0254‑830426342
     [Google Scholar]
  58. ArmentiD. KingR. SifontisN. ConstantinescuS. MoritzM. CosciaL. Update on the teratogenicity of maternal mycophenolate mofetil.J. Pediatr. Genet.20154204205510.1055/s‑0035‑155674327617117
     [Google Scholar]
  59. KingR.W. BacaM.J. ArmentiV.T. KaplanB. Pregnancy outcomes related to mycophenolate exposure in female kidney transplant recipients.Am. J. Transplant.201717115116010.1111/ajt.1392827321569
     [Google Scholar]
  60. TunnicliffeD.J. PalmerS.C. HendersonL. MassonP. CraigJ.C. TongA. Singh-GrewalD. FlancR.S. RobertsM.A. WebsterA.C. StrippoliG.F. Immunosuppressive treatment for proliferative lupus nephritis.Cochrane Database Syst. Rev.201866CD00292229957821
     [Google Scholar]
  61. SaavedraM.Á. SánchezA. MoralesS. ÁngelesU. JaraL.J. Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome.Clin. Rheumatol.20153471211121610.1007/s10067‑015‑2987‑x26050103
     [Google Scholar]
  62. ClowseM.E. MagderL. PetriM. Cyclophosphamide for lupus during pregnancy.Lupus200514859359710.1191/0961203305lu2169oa16175930
     [Google Scholar]
  63. LannesG. EliasF.R. CunhaB. JesusN. KlumbE.M. AlbuquerqueE.M.N. RibeiroF.M. Successful pregnancy after cyclophosphamide therapy for lupus nephritis.Arch. Gynecol. Obstet.2011283Suppl. 1616510.1007/s00404‑011‑1859‑021331538
     [Google Scholar]
  64. MokC.C. ChanP.T. ToC.H. Anti–müllerian hormone and ovarian reserve in systemic lupus erythematosus.Arthritis Rheum.201365120621010.1002/art.3771923044647
     [Google Scholar]
  65. TamirouF. HussonS.N. GrusonD. DebièveF. LauwerysB.R. HoussiauF.A. Brief report: The euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti–müllerian hormone.Arthritis Rheumatol.20176961267127110.1002/art.4007928235250
     [Google Scholar]
  66. ArnaudL. NordinA. LundholmH. SvenungssonE. HellbacherE. WiknerJ. ZickertA. GunnarssonI. Effect of corticosteroids and cyclophosphamide on sex hormone profiles in male patients with systemic lupus erythematosus or systemic sclerosis.Arthritis Rheumatol.20176961272127910.1002/art.4005728141919
     [Google Scholar]
  67. SoaresP.M.F. BorbaE.F. BonfaE. HallakJ. CorrêaA.L. SilvaC.A.A. Gonad evaluation in male systemic lupus erythematosus.Arthritis Rheum.20075672352236110.1002/art.2266017599762
     [Google Scholar]
  68. BlumenfeldZ. MischariO. SchultzN. BoulmanN. Balbir-GurmanA. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases.Semin. Arthritis Rheum.201141334635210.1016/j.semarthrit.2011.05.00821868068
     [Google Scholar]
  69. MarderW. McCuneW.J. WangL. WingJ.J. FissehaS. McConnellD.S. ChristmanG.M. SomersE.C. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.Gynecol. Endocrinol.201228862462710.3109/09513590.2011.65075222296584
     [Google Scholar]
  70. AndreoliL. BertsiasG.K. Agmon-LevinN. BrownS. CerveraR. Costedoat-ChalumeauN. DoriaA. Fischer-BetzR. ForgerF. Moraes-FontesM.F. KhamashtaM. KingJ. LojaconoA. MarchioriF. MeroniP.L. MoscaM. MottaM. OstensenM. PamfilC. RaioL. SchneiderM. SvenungssonE. TektonidouM. YavuzS. BoumpasD. TincaniA. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome.Ann. Rheum. Dis.201776347648510.1136/annrheumdis‑2016‑20977027457513
     [Google Scholar]
  71. LuongS.N. IsaacsA. LiuZ. SinF.E. GilesI. A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone agonists (GnRHa) in women of child-bearing age with autoimmune rheumatic disease.Expert Rev. Clin. Immunol.202016332133310.1080/1744666X.2020.172409132005081
     [Google Scholar]
  72. HalpernW.G. LappinP. ZanardiT. CaiW. CorcoranM. ZhongJ. BakerK.P. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects.Toxicol. Sci.200691258659910.1093/toxsci/kfj14816517838
     [Google Scholar]
  73. Di BattistaM. MarcucciE. ElefanteE. TripoliA. GovernatoG. ZucchiD. TaniC. AlunnoA. One year in review 2018: Systemic lupus erythematosus.Clin. Exp. Rheumatol.201836576377730272543
     [Google Scholar]
  74. StohlW. SchwartingA. OkadaM. ScheinbergM. DoriaA. HammerA.E. KleoudisC. GroarkJ. BassD. FoxN.L. RothD. GordonD. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A fifty-two–week randomized, double-blind, placebo-controlled study.Arthritis Rheumatol.20176951016102710.1002/art.4004928118533
     [Google Scholar]
  75. ZhangF. BaeS.C. BassD. ChuM. EggintonS. GordonD. RothD.A. ZhengJ. TanakaY. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.Ann. Rheum. Dis.201877335536310.1136/annrheumdis‑2017‑21163129295825
     [Google Scholar]
  76. BorbaH.H.L. WiensA. de SouzaT.T. CorrerC.J. PontaroloR. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: Systematic review and meta-analysis.BioDrugs201428221122810.1007/s40259‑013‑0074‑x24190520
     [Google Scholar]
  77. SchwartingA. DooleyM.A. RothD.A. EdwardsL. ThompsonA. WilsonB. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.Lupus201625141587159610.1177/096120331665521527488472
     [Google Scholar]
  78. ShamliyanTA DospinescuP Additional improvements in clinical response from adjuvant biologic response modifiers in adults with moderate to severe systemic lupus erythematosus despite immunosuppressive agents: A systematic review and meta-analysis.Clin Ther.20173971479150610.1016/j.clinthera.2017.05.359
     [Google Scholar]
  79. KnightJ.H. HowardsP.P. SpencerJ.B. TsagarisK.C. LimS.S. Characteristics related to early secondary amenorrhoea and pregnancy among women diagnosed with systemic lupus erythematosus: An analysis using the GOAL study.Lupus Sci. Med.201631e00013910.1136/lupus‑2015‑00013927752335
     [Google Scholar]
  80. YilmazD.E. KirschnerK. DemirciH. HimmerkusN. BachmannS. MutigK. Immunosuppressive calcineurin inhibitor cyclosporine A induces proapoptotic endoplasmic reticulum stress in renal tubular cells.J. Biol. Chem.2022298310158910.1016/j.jbc.2022.10158935033536
     [Google Scholar]
  81. BannerN.R. YacoubM.H. Cyclosporine in thoracic organ transplantation.Elsevier200410.1016/j.transproceed.2004.01.031
     [Google Scholar]
  82. ScaleaJ.R. LeviS.T. AllyW. BraymanK.L. Tacrolimus for the prevention and treatment of rejection of solid organ transplants.Expert Rev. Clin. Immunol.201612333334210.1586/1744666X.2016.112309326588770
     [Google Scholar]
  83. YapD.Y.H. MaM.K.M. MokM.M.Y. KwanL.P.Y. ChanG.C.W. ChanT.M. Long-term data on tacrolimus treatment in lupus nephritis.Rheumatology201453122232223710.1093/rheumatology/keu26524996908
     [Google Scholar]
  84. OgawaH. KamedaH. AmanoK. TakeuchiT. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice.Lupus201019216216910.1177/096120330935032019952069
     [Google Scholar]
  85. LiH. ZhangX. ChenJ. Successful treatment of steroid-refractory systemic lupus erythematosus-associated protein-losing enteropathy using combination therapy with tacrolimus and steroid.Lupus201120101109111110.1177/096120331140676621768173
     [Google Scholar]
  86. LiY. FengX. Efficacy and safety of tacrolimus in systemic lupus erythematosus patients with refractory thrombocytopenia: A retrospective study.Lupus2018271606510.1177/096120331771101128566017
     [Google Scholar]
  87. ChenW. TangX. LiuQ. ChenW. FuP. LiuF. LiaoY. YangZ. ZhangJ. ChenJ. LouT. FuJ. KongY. LiuZ. FanA. RaoS. LiZ. YuX. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial.Am. J. Kidney Dis.201157223524410.1053/j.ajkd.2010.08.03621177013
     [Google Scholar]
  88. ZavadaJ. PešickovaS.S. RyšavaR. OlejarovaM. HorákP. HrnčířZ. RychlíkI. HavrdaM. VítovaJ. LukáčJ. RovenskyJ. TegzovaD. BöhmovaJ. ZadražilJ. HánaJ. DostálC. TesarV. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: The Cyclofa-Lune study.Lupus201019111281128910.1177/096120331037115520605876
     [Google Scholar]
  89. AustinH.A.III IlleiG.G. BraunM.J. BalowJ.E. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.J. Am. Soc. Nephrol.200920490191110.1681/ASN.200806066519297556
     [Google Scholar]
  90. LiuZ. ZhangH. LiuZ. XingC. FuP. NiZ. ChenJ. LinH. LiuF. HeY. HeY. MiaoL. ChenN. LiY. GuY. ShiW. HuW. LiuZ. BaoH. ZengC. ZhouM. Multitarget therapy for induction treatment of lupus nephritis: A randomized trial.Ann. Intern. Med.20151621182610.7326/M14‑103025383558
     [Google Scholar]
  91. MokC.C. ToC.H. YuK.L. HoL.Y. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: A 12-month prospective study.Lupus201322111135114110.1177/096120331350286423995863
     [Google Scholar]
  92. TaoM.J. ChengP. JinL.R. ZhouJ. ShiW. PengH. XuL. LiZ. YuanH. The safety and efficacy of biologic agents in treatment of systemic lupus erythematosus: A network meta-analysis.Pak. J. Med. Sci.20193561680168610.12669/pjms.35.6.77131777515
     [Google Scholar]
  93. FurieR. PetriM. ZamaniO. CerveraR. WallaceD.J. TegzováD. Sanchez-GuerreroJ. SchwartingA. MerrillJ.T. ChathamW.W. StohlW. GinzlerE.M. HoughD.R. ZhongZ.J. FreimuthW. van VollenhovenR.F. BLISS-76 Study Group A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.Arthritis Rheum.201163123918393010.1002/art.3061322127708
     [Google Scholar]
  94. CrowM.K. Type I interferon in the pathogenesis of lupus.J. Immunol.2014192125459546810.4049/jimmunol.100279524907379
     [Google Scholar]
  95. FurieR. KhamashtaM. MerrillJ.T. WerthV.P. KalunianK. BrohawnP. IlleiG.G. DrappaJ. WangL. YooS. CD1013 Study Investigators Anifrolumab, an anti–interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.Arthritis Rheumatol.201769237638610.1002/art.3996228130918
     [Google Scholar]
  96. MorandE.F. FurieR. TanakaY. BruceI.N. AskanaseA.D. RichezC. BaeS.C. BrohawnP.Z. PinedaL. BerglindA. TummalaR. TULIP-2 Trial Investigators Trial of anifrolumab in active systemic lupus erythematosus.N. Engl. J. Med.2020382321122110.1056/NEJMoa191219631851795
     [Google Scholar]
  97. FurieR.A. MorandE.F. BruceI.N. ManziS. KalunianK.C. VitalE.M. Lawrence FordT. GuptaR. HiepeF. SantiagoM. BrohawnP.Z. BerglindA. TummalaR. TULIP-1 study investigators Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial.Lancet Rheumatol.201914e208e21910.1016/S2665‑9913(19)30076‑138229377
     [Google Scholar]
  98. KalunianK.C. FurieR. MorandE.F. BruceI.N. ManziS. TanakaY. WinthropK. HupkaI. ZhangL.J. WertherS. AbreuG. HultquistM. TummalaR. LindholmC. Al-MossawiH. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus.Arthritis Rheumatol.202375225326510.1002/art.4239236369793
     [Google Scholar]
  99. MerrillJ.T. FurieR. WerthV.P. KhamashtaM. DrappaJ. WangL. IlleiG. TummalaR. Anifrolumab effects on rash and arthritis: Impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.Lupus Sci. Med.201851e00028410.1136/lupus‑2018‑00028430588322
     [Google Scholar]
  100. BlumF.R. SampathA.J. FoulkeG.T. Anifrolumab for treatment of refractory cutaneous lupus erythematosus.Clin. Exp. Dermatol.202247111998200110.1111/ced.1533535844070
     [Google Scholar]
  101. LeandroM. IsenbergD.A. Rituximab – The first twenty years.Lupus202130337137710.1177/096120332098266833459161
     [Google Scholar]
  102. NgK.P. CambridgeG. LeandroM.J. EdwardsJ.C.W. EhrensteinM. IsenbergD.A. B cell depletion therapy in systemic lupus erythematosus: Long-term follow-up and predictors of response.Ann. Rheum. Dis.20076691259126210.1136/ard.2006.06712417412738
     [Google Scholar]
  103. LuT.Y.T. NgK.P. CambridgeG. LeandroM.J. EdwardsJ.C.W. EhrensteinM. IsenbergD.A. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patients.Arthritis Care Res.200961448248710.1002/art.2434119333973
     [Google Scholar]
  104. Ramos-CasalsM. SotoM.J. CuadradoM.J. KhamashtaM.A. Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases.Lupus200918976777610.1177/096120330910617419578100
     [Google Scholar]
  105. Turner-StokesT. LuT.Y. EhrensteinM.R. GilesI. RahmanA. IsenbergD.A. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: An evaluation.Rheumatology20115081401140810.1093/rheumatology/ker01821398661
     [Google Scholar]
  106. TerrierB. AmouraZ. RavaudP. HachullaE. JouenneR. CombeB. BonnetC. CacoubP. CantagrelA. De BandtM. FainO. FautrelB. GaudinP. GodeauB. HarléJ.R. HotA. KahnJ.E. LambotteO. LarrocheC. LéoneJ. MeyerO. Pallot-PradesB. PertuisetE. QuartierP. SchaerverbekeT. SibiliaJ. SomogyiA. SoubrierM. VignonE. Bader-MeunierB. MarietteX. GottenbergJ.E. Club Rhumatismes et Inflammation Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry.Arthritis Rheum.20106282458246610.1002/art.2754120506527
     [Google Scholar]
  107. Cobo-IbáñezT. Loza-SantamaríaE. Pego-ReigosaJ.M. MarquésA.O. Rúa-FigueroaÍ. Fernández-NebroA. CálizR.C. López LongoF.J. Muñoz-FernándezS. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review.Semin. Arthritis Rheum.201444217518510.1016/j.semarthrit.2014.04.00224830791
     [Google Scholar]
  108. MerrillJ.T. NeuweltC.M. WallaceD.J. ShanahanJ.C. LatinisK.M. OatesJ.C. UtsetT.O. GordonC. IsenbergD.A. HsiehH.J. ZhangD. BrunettaP.G. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial.Arthritis Rheum.201062122223310.1002/art.2723320039413
     [Google Scholar]
  109. RovinB.H. FurieR. LatinisK. LooneyR.J. FervenzaF.C. Sanchez-GuerreroJ. MaciucaR. ZhangD. GargJ.P. BrunettaP. AppelG. LUNAR Investigator Group Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study.Arthritis Rheum.20126441215122610.1002/art.3435922231479
     [Google Scholar]
  110. KraaijT. ArendsE.J. van DamL.S. KamerlingS.W.A. van DaeleP.L.A. BredewoldO.W. RayA. BakkerJ.A. SchererH.U. HuizingaT.J.W. RabelinkT.J. van KootenC. TengY.K.O. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.Nephrol. Dial. Transplant.20213681474148310.1093/ndt/gfaa11732591783
     [Google Scholar]
  111. RupertoN. HanrahanL.M. AlarcónG.S. BelmontH.M. BreyR.L. BrunettaP. BuyonJ.P. CostnerM.I. CroninM.E. DooleyM.A. FilocamoG. FiorentinoD. FortinP.R. FranksA.G.Jr GilkesonG. GinzlerE. GordonC. GrossmanJ. HahnB. IsenbergD.A. KalunianK.C. PetriM. SammaritanoL. Sánchez-GuerreroJ. SontheimerR.D. StrandV. UrowitzM. von FeldtJ.M. WerthV.P. MerrillJ.T. Lupus Foundation of America, Inc. International Flare Consensus Initiative International consensus for a definition of disease flare in lupus.Lupus201120545346210.1177/096120331038844521148601
     [Google Scholar]
  112. GordonC. SutcliffeN. SkanJ. StollT. IsenbergD.A. Definition and treatment of lupus flares measured by the BILAG index.Br. J. Rheumatol.200342111372137910.1093/rheumatology/keg38212810926
     [Google Scholar]
  113. PetriM. SinghS. TesfasyoneH. MalikA. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: A prospective study.J. Rheumatol.200936112476248010.3899/jrheum.09001919833757
     [Google Scholar]
  114. ContiF. CeccarelliF. PerriconeC. LecceseI. MassaroL. PacucciV.A. TrugliaS. MirandaF. SpinelliF.R. AlessandriC. ValesiniG. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: Results from a monocentric cohort.Lupus201625771972610.1177/096120331562719926821965
     [Google Scholar]
  115. KoutsonikoliA. TrachanaM. HeidichA.B. GalanopoulouV. Pratsidou-GertsiP. GaryphallosA. Dissecting the damage in northern greek patients with childhood-onset systemic lupus erythematosus: A retrospective cohort study.Rheumatol. Int.20153571225123210.1007/s00296‑014‑3209‑625586653
     [Google Scholar]
  116. Tsang-A-SjoeM.W.P. Bultinki.e.M. HeslingaM. VoskuylA.E. Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus.Rheumatology201756112112810.1093/rheumatology/kew37727803306
     [Google Scholar]
  117. Ugarte-GilM.F. Acevedo-VásquezE. AlarcónG.S. Pastor-AsurzaC.A. Alfaro-LozanoJ.L. Cucho-VenegasJ.M. SegamiM.I. WojdylaD. SorianoE.R. DrenkardC. BrenolJ.C. de Oliveira e Silva MontandonA.C. Lavras CostallatL.T. MassardoL. Molina-RestrepoJ.F. Guibert-ToledanoM. SilveiraL.H. AmigoM.C. Barile-FabrisL.A. Chacón-DíazR. Esteva-SpinettiM.H. Pons-EstelG.J. McGwinG.Jr Pons-EstelB.A. GLADEL The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: Data from a multiethnic Latin American cohort.Ann. Rheum. Dis.20157461019102310.1136/annrheumdis‑2013‑20462024525909
     [Google Scholar]
  118. KasitanonN. IntaniwetT. WangkaewS. PantanaS. SukitawutW. LouthrenooW. The clinically quiescent phase in early-diagnosed SLE patients: inception cohort study.Rheumatology201554586887510.1093/rheumatology/keu40625339640
     [Google Scholar]
  119. PetriM.A. van VollenhovenR.F. BuyonJ. LevyR.A. NavarraS.V. CerveraR. ZhongZ.J. FreimuthW.W. BLISS-52 and BLISS-76 Study Groups Baseline predictors of systemic lupus erythematosus flares: Data from the combined placebo groups in the phase III belimumab trials.Arthritis Rheum.20136582143215310.1002/art.3799523754628
     [Google Scholar]
  120. SteimanA.J. GladmanD.D. IbañezD. UrowitzM.B. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period.Arthritis Care Res.201264451151810.1002/acr.2156822162433
     [Google Scholar]
  121. WeissJ.E. SisonC.P. IlowiteN.T. GottliebB.S. EberhardB.A. Flares in pediatric systemic lupus erythematosus.J. Rheumatol.20073461341134417477466
     [Google Scholar]
  122. FurieR.A. WallaceD.J. AranowC. FettiplaceJ. WilsonB. MistryP. RothD.A. GordonD. Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus.Arthritis Rheumatol.201870686887710.1002/art.4043929409143
     [Google Scholar]
  123. GinzlerE.M. WallaceD.J. MerrillJ.T. FurieR.A. StohlW. ChathamW.W. WeinsteinA. McKayJ.D. McCuneW.J. ZhongZ.J. FreimuthW.W. PetriM.A. LBSL02/99 Study Group Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.J. Rheumatol.201441230030910.3899/jrheum.12136824187095
     [Google Scholar]
  124. FurieR. MorandE.F. AskanaseA.D. VitalE.M. MerrillJ.T. KalyaniR.N. AbreuG. PinedaL. TummalaR. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.Lupus20213081254126310.1177/0961203321101426733977796
     [Google Scholar]
  125. AlsowaidaN. AlrasheedM. MayetA. AlsuwaidaA. OmairM.A. Medication adherence, depression and disease activity among patients with systemic lupus erythematosus.Lupus201827232733210.1177/096120331772558528825347
     [Google Scholar]
  126. GrenardJ.L. MunjasB.A. AdamsJ.L. SuttorpM. MaglioneM. McGlynnE.A. Depression and medication adherence in the treatment of chronic diseases in the United States: A meta-analysis.J Gen Intern Med.2011261011751182
     [Google Scholar]
  127. JulianLJ. Depression, medication adherence, and service utilization in systemic lupus erythematosus.Arthritis Rheum.2009612240246
     [Google Scholar]
  128. De GeestS. SabatéE. World Health Organization Adherence to long-term therapies: Evidence for action.Eur. J. Cardiovasc. Nurs.20032432310.1016/S1474‑5151(03)00091‑414667488
     [Google Scholar]
  129. AlmalkiM. FitzgeraldG. ClarkM. Health care system in Saudi Arabia: An overview.East. Mediterr. Health J.2011171078479310.26719/2011.17.10.78422256414
     [Google Scholar]
  130. GillJ.M. QuiselA.M. RoccaP.V. WaltersD.T. Diagnosis of systemic lupus erythematosus.Am. Fam. Physician200368112179218614677663
     [Google Scholar]
  131. ClarkeA.E. WeinsteinA. PiscitelloA. HeerA. ChandraT. DoshiS. WegenerJ. GossT.F. PowellT. Evaluation of the economic benefit of earlier systemic lupus erythematosus (SLE) diagnosis using a multivariate assay panel (MAP).ACR Open Rheumatol.202021162963910.1002/acr2.1117733044050
     [Google Scholar]
  132. AljohaniR. GladmanD.D. SuJ. UrowitzM.B. Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics.Clin. Rheumatol.20173681773177810.1007/s10067‑017‑3713‑728589322
     [Google Scholar]
  133. KernderA. RichterJ.G. Fischer-BetzR. Winkler-RohlfingB. BrinksR. AringerM. SchneiderM. ChehabG. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort.Lupus202130343143810.1177/096120332098344533402036
     [Google Scholar]
  134. KarremahM.F.Jnr HassanR.Y. FaloudahA.Z. AlharbiL.K. ShodariA.F. RahbeeniA.A. AlharaziN.K. BinjabiA.Z. CheikhM.M. MansafiH. AbdulazizS. HusseinA.H. AlhazmiA. AlmoallimH.M. From symptoms to diagnosis: An observational study of the journey of SLE patients in Saudi Arabia.Open Access Rheumatol.20221410311110.2147/OARRR.S36283335791408
     [Google Scholar]
  135. Company-QuirogaJ. Alique-GarcíaS. Romero-MatéA. Current insights into the management of discoid lupus erythematosus.Clin. Cosmet. Investig. Dermatol.20191272173210.2147/CCID.S18482431632120
     [Google Scholar]
  136. BlakeS.C. DanielB.S. Cutaneous lupus erythematosus: A review of the literature.Int J Womens Dermatol.2019315320329
     [Google Scholar]
  137. DoeglasH.M.G. Chronic discoid lupus erythematosus treated with triamcinolone and plastic occlusion.Dermatology1964128538438610.1159/00025476914162995
     [Google Scholar]
  138. BjornnbergA. HellgrenL. Treatment of chronic discoid lupus erythematosus with fluocinolone acetonide ointment.Br. J. Dermatol.196375415616010.1111/j.1365‑2133.1963.tb13959.x13971327
     [Google Scholar]
  139. BjornbergA. HellgrenL. Topical treatment of chronic discoid lupus erythematosus with betamethason-17-valerate and fluocinolone acetonie-a double blind study.Indian J. Dermatol.196612117185341750
     [Google Scholar]
  140. SárdyM. RuzickaT. KuhnA. Topical calcineurin inhibitors in cutaneous lupus erythematosus.Arch. Dermatol. Res.20093011939810.1007/s00403‑008‑0894‑618797893
     [Google Scholar]
  141. TzellosT.G. KouvelasD. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: An evidence-based evaluation.Eur. J. Clin. Pharmacol.200864433734110.1007/s00228‑007‑0421‑218157526
     [Google Scholar]
  142. O’KaneD. McCourtC. MeggittS. D’CruzD.P. OrteuC.H. BentonE. WahieS. UttonS. HashmeM. Mohd MustapaM.F. ExtonL.S. British Association of Dermatologists’ Clinical Standards Unit British association of dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021.Br. J. Dermatol.202118561112112310.1111/bjd.2059734170012
     [Google Scholar]
  143. KuhnA. AbererE. Bata-CsörgőZ. CaproniM. DreherA. FrancesC. S2k guideline for treatment of cutaneous lupus erythematosus – guided by the european dermatology forum (EDF) in cooperation with the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol.2017313389404
     [Google Scholar]
  144. ChangA.Y. PietteE.W. FoeringK.P. TenhaveT.R. OkawaJ. WerthV.P. Response to antimalarial agents in cutaneous lupus erythematosus: A prospective analysis.Arch. Dermatol.2011147111261126710.1001/archdermatol.2011.19121768444
     [Google Scholar]
  145. RothfieldN. SontheimerR.D. BernsteinM. Lupus erythematosus: Systemic and cutaneous manifestations.Clin. Dermatol.200624534836210.1016/j.clindermatol.2006.07.01416966017
     [Google Scholar]
  146. CallenJ.P. SpencerL.V. BurrussJ.B. HoltmanJ. Azathioprine.Arch. Dermatol.1991127451552210.1001/archderm.1991.045100100830082006876
     [Google Scholar]
  147. IslamM.N. HossainM. HaqS.A. AlamM.N. Ten KloosterP.M. RaskerJ.J. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus.Int. J. Rheum. Dis.2012151626810.1111/j.1756‑185X.2011.01665.x22324948
     [Google Scholar]
  148. LuQ. LongH. ChowS. HidayatS. DanartiR. ListiawanY. DengD. GuoQ. FangH. TaoJ. ZhaoM. XiangL. CheN. LiF. ZhaoH. LauC.S. IpF.C. HoK.M. PalizaA.C. VichethC. GodseK. ChoS. SeowC.S. MiyachiY. KhangT.H. UngpakornR. GaladariH. ShahR. YangK. ZhouY. SelmiC. SawalhaA.H. ZhangX. ChenY. LinC.S. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus.J. Autoimmun.202112310270710.1016/j.jaut.2021.10270734364171
     [Google Scholar]
  149. PettyAJ FloydL HendersonC NicholasMW Cutaneous lupus erythematosus: Progress and challenges.Curr Allergy Asthma Rep.202020512
     [Google Scholar]
  150. LarosaM. Del RossT. CalligaroA. FavaroM. ZanattaE. IaccarinoL. Clinical outcomes and predictors of maternal and fetal complications in pregnancies of patients with systemic lupus erythematosus.Expert Rev Clin Immunol.2019617627
     [Google Scholar]
  151. RezkM. EllakwaH. Al-HalabyA. ShaheenA. ZahranA. BadrH. RETRACTED ARTICLE: Predictors of poor obstetric outcome in women with systemic lupus erythematosus: A 10-year experience of a university hospital.J. Matern. Fetal Neonatal Med.201730172031203510.1080/14767058.2016.123624427628505
     [Google Scholar]
  152. ManziS. Sánchez-GuerreroJ. MerrillJ.T. FurieR. GladmanD. NavarraS.V. GinzlerE.M. D’CruzD.P. DoriaA. CooperS. ZhongZ.J. HoughD. FreimuthW. PetriM.A. BLISS-52 and BLISS-76 Study Groups Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials.Ann. Rheum. Dis.201271111833183810.1136/annrheumdis‑2011‑20083122550315
     [Google Scholar]
  153. IaccarinoL. BettioS. ReggiaR. ZenM. FrassiM. AndreoliL. GattoM. PiantoniS. NalottoL. FranceschiniF. LarosaM. FrediM. PunziL. TincaniA. DoriaA. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus.Arthritis Care Res.201769111512310.1002/acr.2297127390293
     [Google Scholar]
  154. VashishtP. BorghoffK. O’DellJ.R. Hearth-HolmesM. Belimumab for the treatment of recalcitrant cutaneous lupus.Lupus201726885786410.1177/096120331668209728121495
     [Google Scholar]
  155. ParodisI. GomezA. FrodlundM. JönsenA. ZickertA. SjöwallC. BengtssonA.A. GunnarssonI. Smoking reduces the efficacy of belimumab in mucocutaneous lupus.Expert Opin. Biol. Ther.201818891192010.1080/14712598.2018.149471929958508
     [Google Scholar]
  156. QariF.A. Clinical pattern of systemic lupus erythematosus in Western Saudi Arabia.Saudi Med. J.200223101247125012436131
     [Google Scholar]
  157. Al ArfajA.S. KhalilN. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia.Lupus200918546547310.1177/096120330810066019318403
     [Google Scholar]
  158. AlhassanN. AlmetriT. AbualsoudS. MalhisA. Al-QahtaniK. AlwaznaA. SalloumN. ZaeriB. HegazyA. MohamedS. BashawriY. Al GhanimN. Causes of hospitalization for systemic lupus erythematosus in saudi arabia compared with the global setting: A retrospective single-center observational study.Cureus20211310e1885810.7759/cureus.1885834804711
     [Google Scholar]
  159. Al-MayoufS. AbdwaniR. Al-brawiS. Familial juvenile systemic lupus erythematosus in Arab children.Rheumatol. Int.20123271939194310.1007/s00296‑011‑1886‑y21461717
     [Google Scholar]
  160. SaletraA. OlesińskaM. Quality of life in systemic lupus erythematosus and its measurement.Reumatologia2018561455410.5114/reum.2018.7475029686443
     [Google Scholar]
  161. NavarraS.V. GuzmánR.M. GallacherA.E. HallS. LevyR.A. JimenezR.E. LiE.K.M. ThomasM. KimH.Y. LeónM.G. TanasescuC. NasonovE. LanJ.L. PinedaL. ZhongZ.J. FreimuthW. PetriM.A. BLISS-52 Study Group Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial.Lancet2011377976772173110.1016/S0140‑6736(10)61354‑221296403
     [Google Scholar]
  162. CollinsC.E. Cortes-HernándezJ. GarciaM.A. von KempisJ. SchwartingA. ToumaZ. KurtineczM. GairyK. Real-world effectiveness of belimumab in the treatment of systemic lupus erythematosus: Pooled analysis of multi-country data from the observe studies.Rheumatol. Ther.20207494996510.1007/s40744‑020‑00243‑233206344
     [Google Scholar]
  163. WallaceD.J. AtsumiT. DanielsM. HammerA. MeizlikP. QuasnyH. SchwartingA. ZhangF. RothD.A. Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data.Lupus202231131649165910.1177/0961203322113118336206400
     [Google Scholar]
  164. FurieR. RovinB.H. HoussiauF. MalvarA. TengY.K.O. ContrerasG. AmouraZ. YuX. MokC.C. SantiagoM.B. SaxenaA. GreenY. JiB. KleoudisC. BurrissS.W. BarnettC. RothD.A. Two-year, randomized, controlled trial of belimumab in lupus nephritis.N. Engl. J. Med.2020383121117112810.1056/NEJMoa200118032937045
     [Google Scholar]
  165. AbidN. KhanA.S. OtaibiF.H.A. Systemic lupus erythematosus (SLE) in the eastern region of Saudi Arabia. A comparative study.Lupus201322141529153310.1177/096120331350054823934402
     [Google Scholar]
  166. HellerT. AhmedM. SiddiqqiA. WallrauchC. BahlasS. Systemic lupus erythematosus in Saudi Arabia: Morbidity and mortality in a multiethnic population.Lupus2007161190891410.1177/096120330708111217971366
     [Google Scholar]
  167. HamedH.O. AhmedS.R. AlzolibaniA. KamalM.M. MostafaM.S. GamalR.M. AtallahD.A.A. Abd-El-AallD.E.M. Does cutaneous lupus erythematosus have more favorable pregnancy outcomes than systemic disease? A two-center study.Acta Obstet. Gynecol. Scand.201392893494210.1111/aogs.1215823621378
     [Google Scholar]
  168. GuoZ. ZhangZ. PrajapatiM. LiY. Lymphopenia caused by virus infections and the mechanisms beyond.Viruses2021139187610.3390/v1309187634578457
     [Google Scholar]
  169. NeunertC. LimW. CrowtherM. CohenA. SolbergL.Jr CrowtherM.A. American Society of Hematology The american society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia.Blood2011117164190420710.1182/blood‑2010‑08‑30298421325604
     [Google Scholar]
  170. WafaA. HichamH. NaoufalR. HajarK. RachidR. SouadB. MounaM. ZoubidaM.T. MohamedA. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 20 Moroccan adult patients.Clin. Rheumatol.20224172021203310.1007/s10067‑022‑06055‑935179662
     [Google Scholar]
  171. KleinA. MoladY. Hematological manifestations among patients with rheumatic diseases.Acta Haematol.2021144440341210.1159/00051175933221805
     [Google Scholar]
  172. AringerM. Who will respond to type I interferon receptor blockade in SLE?Lancet Rheumatol.202244e234e23610.1016/S2665‑9913(21)00370‑238288920
     [Google Scholar]
  173. YangH. LiuH. XuD. ZhaoL. WangQ. LengX. ZhengW. ZhangF. TangF. ZhangX. Pregnancy-related systemic lupus erythematosus: Clinical features, outcome and risk factors of disease flares - A case control study.PLoS One201498e10437510.1371/journal.pone.0104375
     [Google Scholar]
  174. BorellaE. LojaconoA. GattoM. AndreoliL. TagliettiM. IaccarinoL. CasigliaE. PunziL. TincaniA. DoriaA. Predictors of maternal and fetal complications in SLE patients: A prospective study.Immunol. Res.2014602-317017610.1007/s12026‑014‑8572‑625398639
     [Google Scholar]
  175. SaavedraM.A. SánchezA. MoralesS. Navarro-ZarzaJ.E. ÁngelesU. JaraL.J. Primigravida is associated with flare in women with systemic lupus erythematosus.Lupus201524218018510.1177/096120331455211625253570
     [Google Scholar]
  176. BuyonJ.P. KimM.Y. GuerraM.M. LaskinC.A. PetriM. LockshinM.D. SammaritanoL. BranchD.W. PorterT.F. SawitzkeA. MerrillJ.T. StephensonM.D. CohnE. GarabetL. SalmonJ.E. Predictors of pregnancy outcomes in patients with lupus.Ann. Intern. Med.2015163315316310.7326/M14‑223526098843
     [Google Scholar]
  177. DaoK.H. BermasB.L. Systemic lupus erythematosus management in pregnancy.Int. J. Womens Health20221419921110.2147/IJWH.S28260435210867
     [Google Scholar]
  178. KnightC. Nelson-PiercyC. Management of systemic lupus erythematosus during pregnancy: Challenges and solutions.Open Access Rheumatol.20179375310.2147/OARRR.S8782828331377
     [Google Scholar]
  179. KohJ.H. KoH.S. LeeJ. JungS.M. KwokS-K. JuJ.H. ParkS-H. Pregnancy and patients with preexisting lupus nephritis: 15 years of experience at a single center in Korea.Lupus201524776477210.1177/096120331557271525712250
     [Google Scholar]
  180. ClowseM.E.B. MagderL. WitterF. PetriM. Hydroxychloroquine in lupus pregnancy.Arthritis Rheum.200654113640364710.1002/art.2215917075810
     [Google Scholar]
  181. KohJ.H. KoH.S. KwokS-K. JuJ.H. ParkS-H. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus.Lupus201524221021710.1177/096120331455535225305214
     [Google Scholar]
  182. EudyA.M. Siega-RizA.M. EngelS.M. FranceschiniN. HowardA.G. ClowseM.E.B. PetriM. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus.Ann. Rheum. Dis.2018776855-6010.1136/annrheumdis‑2017‑21253529463519
     [Google Scholar]
  183. SaavedraM.Á. Miranda-HernándezD. Lara-MejíaA. SánchezA. MoralesS. Cruz-ReyesC. Cruz-DomínguezP. MedinaG. JaraL.J. Use of antimalarial drugs is associated with a lower risk of preeclampsia in lupus pregnancy: A prospective cohort study.Int. J. Rheum. Dis.202023563364010.1111/1756‑185X.1383032227576
     [Google Scholar]
  184. SeoM.R. ChaeJ. KimY.M. ChaH.S. ChoiS.J. OhS. RohC.R. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.Lupus201928672273010.1177/096120331984334330971164
     [Google Scholar]
  185. KalokA. Abdul CaderR. IndirayaniI. Abdul KarimA.K. ShahS.A. Mohamed IsmailN.A. OmarM.H. ShafieeM.N. Pregnancy outcomes in systemic lupus erythematosus (SLE) women.Horm. Mol. Biol. Clin. Investig.20194032019000710.1515/hmbci‑2019‑000731553696
     [Google Scholar]
  186. ClowseM.E.B. EudyA.M. BalevicS. Sanders-SchmidlerG. KosinskiA. Fischer-BetzR. GladmanD.D. MoladY. NalliC. MokbelA. TincaniA. UrowitzM. BayC. van NoordM. PetriM. Hydroxychloroquine in the pregnancies of women with lupus: A meta-analysis of individual participant data.Lupus Sci. Med.202291e00065110.1136/lupus‑2021‑00065135318256
     [Google Scholar]
  187. KroeseS.J. AbheidenC.N.H. BlomjousB.S. van LaarJ.M. DerksenR.W.H.M. Bultink i.e. M. VoskuylA.E. LelyA.T. de BoerM.A. de VriesJ.I.P. Fritsch-StorkR.D.E. Maternal and perinatal outcome in women with systemic lupus erythematosus: A retrospective bicenter cohort study.J. Immunol. Res.201720171910.1155/2017/824587929094052
     [Google Scholar]
  188. LevyR.A. VilelaV.S. CataldoM.J. RamosR.C. DuarteJ.L. TuraB.R. AlbuquerqueM. JesúsN.R. Hydroxychloroquine (HCQ) in lupus pregnancy: Double-blind and placebo-controlled study.Lupus200110640140410.1191/09612030167864613711434574
     [Google Scholar]
  189. DavidsonK.W. BarryM.J. MangioneC.M. CabanaM. CaugheyA.B. DavisE.M. DonahueK.E. DoubeniC.A. KubikM. LiL. OgedegbeG. PbertL. SilversteinM. SimonM.A. StevermerJ. TsengC.W. WongJ.B. US Preventive Services Task Force Aspirin use to prevent preeclampsia and related morbidity and mortality.JAMA2021326121186119110.1001/jama.2021.1478134581729
     [Google Scholar]
  190. RobergeS. GiguèreY. VillaP. NicolaidesK. VainioM. ForestJ-C. von DadelszenP. VaimanD. TappS. BujoldE. Early administration of low- dose aspirin for the prevention of severe and mild preeclampsia: A systematic review and meta-analysis.Am. J. Perinatol.201229755155622495898
     [Google Scholar]
  191. WapnerR.J. FriedmanA.M. Inferring risk from a common drug exposure in pregnancy.BJOG201912613156810.1111/1471‑0528.1592331479565
     [Google Scholar]
  192. Götestam SkorpenC. HoeltzenbeinM. TincaniA. Fischer-BetzR. ElefantE. ChambersC. da SilvaJ. Nelson-PiercyC. CetinI. Costedoat-ChalumeauN. DolhainR. FörgerF. KhamashtaM. Ruiz-IrastorzaG. ZinkA. VencovskyJ. CutoloM. CaeyersN. ZumbühlC. ØstensenM. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.Ann. Rheum. Dis.201675579581010.1136/annrheumdis‑2015‑20884026888948
     [Google Scholar]
  193. ClowseM.E.B. MagderL.S. WitterF. PetriM. The impact of increased lupus activity on obstetric outcomes.Arthritis Rheum.200552251452110.1002/art.2086415692988
     [Google Scholar]
  194. ChakravartyE.F. ColónI. LangenE.S. NixD.A. El-SayedY.Y. GenoveseM.C. DruzinM.L. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus.Am. J. Obstet. Gynecol.200519261897190410.1016/j.ajog.2005.02.06315970846
     [Google Scholar]
  195. Abou-NassarK. KarshJ. GiuliviA. AllanD. Successful prevention of thrombotic thrombocytopenic purpura (TTP) relapse using monthly prophylactic plasma exchanges throughout pregnancy in a patient with systemic lupus erythematosus and a prior history of refractory TTP and recurrent fetal loss.Transfus. Apheresis Sci.2010431293110.1016/j.transci.2010.05.00220547472
     [Google Scholar]
  196. BuyonJ.P. ClancyR.M. FriedmanD.M. Cardiac manifestations of neonatal lupus erythematosus: Guidelines to management, integrating clues from the bench and bedside.Nat. Clin. Pract. Rheumatol.20095313914819252519
     [Google Scholar]
  197. JaeggiE.T. HamiltonR.M. SilvermanE.D. ZamoraS.A. HornbergerL.K. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block.J. Am. Coll. Cardiol.200239113013710.1016/S0735‑1097(01)01697‑711755298
     [Google Scholar]
  198. Ruiz-IrastorzaG. KhamashtaM.A. Lupus and pregnancy: Ten questions and some answers.Lupus200817541642010.1177/096120330809002718490419
     [Google Scholar]
  199. ShimadaH. WakiyaR. KanenishiK. MiyatakeN. NakashimaS. MansourM.M.F. KatoM. MiyagiT. SugiharaK. UshioY. MinoR. MizusakiM. KamedaT. KadowakiN. DobashiH. Preterm birth is strongly affected by the glucocorticoid dose during pregnancy in women complicated by systemic lupus erythematosus.Arthritis Res. Ther.20222411010.1186/s13075‑021‑02699‑134980235
     [Google Scholar]
  200. GullerS. KongL. WozniakR. LockwoodC.J. Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: A potential role in preterm rupture of the fetal membranes.J. Clin. Endocrinol. Metab.1995807224422507608287
     [Google Scholar]
  201. LockwoodC.J. RadunovicN. NasticD. PetkovicS. AignerS. BerkowitzG.S. Corticotropin-releasing hormone and related pituitary-adrenal axis hormones in fetal and maternal blood during the second half of pregnancy.J. Perinat. Med.199624324325110.1515/jpme.1996.24.3.2438827573
     [Google Scholar]
  202. ØstensenM. KhamashtaM. LockshinM. ParkeA. BrucatoA. CarpH. DoriaA. RaiR. MeroniP. CetinI. DerksenR. BranchW. MottaM. GordonC. Ruiz-IrastorzaG. SpinilloA. FriedmanD. CimazR. CzeizelA. PietteJ. CerveraR. LevyR.A. ClementiM. De CarolisS. PetriM. ShoenfeldY. FadenD. ValesiniG. TincaniA. Anti-inflammatory and immunosuppressive drugs and reproduction.Arthritis Res. Ther.20068320910.1186/ar195716712713
     [Google Scholar]
  203. BuckleyL.M. BullaboyC.A. LeichtmanL. MarquezM. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother.Arthritis Rheum.199740597197310.1002/art.17804005279153561
     [Google Scholar]
  204. MilunskyA. GraefJ.W. GaynorM.F.Jr Methotrexate-induced congenital malformations.J. Pediatr.196872679079510.1016/S0022‑3476(68)80430‑55652604
     [Google Scholar]
  205. IchinoseK. SatoS. KitajimaY. HoraiY. FujikawaK. UmedaM. FukuiS. NishinoA. KogaT. KawashiriS.Y. IwamotoN. TamaiM. NakamuraH. OriguchiT. YasuhiI. MasuzakiH. KawakamiA. The efficacy of adjunct tacrolimus treatment in pregnancy outcomes in patients with systemic lupus erythematosus.Lupus20182781312132010.1177/096120331877053629665758
     [Google Scholar]
  206. LateefA. PetriM. Systemic lupus erythematosus and pregnancy.Rheum. Dis. Clin. North Am.201743221522610.1016/j.rdc.2016.12.00928390564
     [Google Scholar]
  207. de BoerN.K.H. JarbandhanS.V.A. de GraafP. MulderC.J.J. van ElburgR.M. van BodegravenA.A. Azathioprine use during pregnancy: Unexpected intrauterine exposure to metabolites.Am. J. Gastroenterol.200610161390139210.1111/j.1572‑0241.2006.00538.x16771965
     [Google Scholar]
  208. SifontisN.M. CosciaL.A. ConstantinescuS. LavelanetA.F. MoritzM.J. ArmentiV.T. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus.Transplantation200682121698170210.1097/01.tp.0000252683.74584.2917198262
     [Google Scholar]
  209. KaoJ.H. LanT.Y. LuC.H. ChengC.F. HuangY.M. ShenC.Y. HsiehS.C. Pregnancy outcomes in patients treated with belimumab: Report from real-world experience.Semin. Arthritis Rheum.202151596396810.1016/j.semarthrit.2021.06.00534403811
     [Google Scholar]
  210. LimW. Antiphospholipid syndrome.Hematology20132013167568010.1182/asheducation‑2013.1.67524319251
     [Google Scholar]
  211. TektonidouM.G. LaskariK. PanagiotakosD.B. MoutsopoulosH.M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.Arthritis Care Res.2009611293610.1002/art.2423219116963
     [Google Scholar]
  212. WahlD.G. GuilleminF. de MaistreE. PerretC. LecompteT. ThibautG. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysis.Lupus19976546747310.1177/0961203397006005109229367
     [Google Scholar]
  213. MustonenP. LehtonenK.V. JavelaK. PuurunenM. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: A nationwide prospective study.Lupus201423141468147610.1177/096120331454541025164304
     [Google Scholar]
  214. SomersE. MagderL.S. PetriM. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.J. Rheumatol.200229122531253612465147
     [Google Scholar]
  215. PengoV. RuffattiA. LegnaniC. GreseleP. BarcellonaD. ErbaN. TestaS. MarongiuF. BisonE. DenasG. BanzatoA. Padayattil JoseS. IlicetoS. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.J. Thromb. Haemost.20108223724210.1111/j.1538‑7836.2009.03674.x19874470
     [Google Scholar]
  216. PengoV. TestaS. MartinelliI. GhirarduzziA. LegnaniC. GreseleP. PassamontiS.M. BisonE. DenasG. JoseS.P. BanzatoA. RuffattiA. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant.Thromb. Res.20151351464910.1016/j.thromres.2014.10.01325456002
     [Google Scholar]
  217. TektonidouM.G. AndreoliL. LimperM. AmouraZ. CerveraR. Costedoat-ChalumeauN. CuadradoM.J. DörnerT. Ferrer-OliverasR. HamblyK. KhamashtaM.A. KingJ. MarchioriF. MeroniP.L. MoscaM. PengoV. RaioL. Ruiz-IrastorzaG. ShoenfeldY. StojanovichL. SvenungssonE. WahlD. TincaniA. WardM.M. EULAR recommendations for the management of antiphospholipid syndrome in adults.Ann. Rheum. Dis.201978101296130410.1136/annrheumdis‑2019‑21521331092409
     [Google Scholar]
  218. GergianakiI. GarantziotisP. AdamichouC. SaridakisI. SpyrouG. SidiropoulosP. BertsiasG. High comorbidity burden in patients with sle: Data from the community-based lupus registry of crete.J. Clin. Med.202110599810.3390/jcm1005099833801229
     [Google Scholar]
  219. HansenR.B. SimardJ.F. FaurschouM. JacobsenS. Distinct patterns of comorbidity prior to diagnosis of incident systemic lupus erythematosus in the Danish population.J. Autoimmun.202112310269210.1016/j.jaut.2021.10269234364172
     [Google Scholar]
  220. MebrahtuT.F. MorganA.W. WestR.M. StewartP.M. Pujades-RodriguezM. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: A population-based cohort study.CMAJ202019212E295E30110.1503/cmaj.19101232392512
     [Google Scholar]
  221. SinicatoN.A. da Silva CardosoP.A. AppenzellerS. Risk factors in cardiovascular disease in systemic lupus erythematosus.Curr. Cardiol. Rev.201391151923463953
     [Google Scholar]
  222. YangL. TaoJ. TangX. WangY. HeX. XuG. RenY. TuY. Prevalence and correlation of conventional and lupus-specific risk factors for cardiovascular disease in Chinese systemic lupus erythematosus patients.J. Eur. Acad. Dermatol. Venereol.20122619510110.1111/j.1468‑3083.2011.04211.x21851424
     [Google Scholar]
  223. SkamraC. Ramsey-GoldmanR. Management of cardiovascular complications in systemic lupus erythematosus.Int. J. Clin. Rheumatol.2010517510010.2217/ijr.09.7320305727
     [Google Scholar]
  224. AlbrechtK. RedekerI. AringerM. MarschallU. StrangfeldA. CallhoffJ. Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: Analysis of a claims data cohort.Lupus Sci. Med.202181e00052610.1136/lupus‑2021‑00052634433613
     [Google Scholar]
  225. Al-MayoufS.M. Systemic lupus erythematosus in Saudi children: Long-term outcomes.Int. J. Rheum. Dis.2013161566010.1111/1756‑185x.1202023441773
     [Google Scholar]
  226. Al HamziH. AlhaymouniB. Al ShaikhA. Al-MayoufS.M. Outcome of adult Saudi patients with childhood-onset systemic lupus erythematosus.Clin. Exp. Rheumatol.201432698498825152255
     [Google Scholar]
  227. WalbiI.A. AlbarqiH.A. AlghanimN.S. AlbadiM.A. Al MaimouniH.M. AlkahtaniS.A. AlshabiA.M. AlaliA.S. AlqahtaniF. Al-NajjarA.H. HazzaziM.A. AlanaziD.S. SabeiA.A. AlsaweedO.S. AlajraR.K. AlqhtaniH. Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: A multicenter retrospective cohort.J. Int. Med. Res.202250410.1177/0300060522109036335387504
     [Google Scholar]
  228. LinY.J. ChienC.C. HoC.H. ChenH.A. ChenC.Y. Increased risk of type 2 diabetes in patients with systemic lupus erythematosus: A nationwide cohort study in Taiwan.Medicine202210151e3252010.1097/MD.000000000003252036595866
     [Google Scholar]
  229. SomailyM. AsiriS. AseeryL. Causes and outcomes of hospitalization among systemic lupus erythematosus patients in aseer central hospital, Saudi Arabia: A retrospective study.Egypt. J. Hosp. Med.20187112358236410.12816/0045312
     [Google Scholar]
  230. WuJ. MackieS.L. Pujades-RodriguezM. Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: A population-based cohort analysis.BMJ Open Diabetes Res. Care202081e00122010.1136/bmjdrc‑2020‑00122032719077
     [Google Scholar]
  231. SuhS. ParkM.K. Glucocorticoid-induced diabetes mellitus: An important but overlooked problem.Endocrinol. Metab.201732218018910.3803/EnM.2017.32.2.18028555464
     [Google Scholar]
  232. BrownE.S. ChandlerP.A. Mood and cognitive changes during systemic corticosteroid therapy.Prim. Care Companion J. Clin. Psychiatry200131172115014624
     [Google Scholar]
  233. SmithS.M. ValeW.W. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress.Dialogues Clin. Neurosci.20068438339510.31887/DCNS.2006.8.4/ssmith17290797
     [Google Scholar]
  234. BazzanM. VaccarinoA. MarlettoF. Systemic lupus erythematosus and thrombosis.Thromb. J.20151311610.1186/s12959‑015‑0043‑325908929
     [Google Scholar]
  235. XiaJ LuoR GuoS YangY GeS XuG Prevalence and risk factors of reduced bone mineral density in systemic lupus erythematosus patients: A meta-analysis.Biomed Res Int.20192019373164810.1155/2019/3731648
     [Google Scholar]
  236. AndersonE. NietertP.J. KamenD.L. GilkesonG.S. Ethnic disparities among patients with systemic lupus erythematosus in South Carolina.J. Rheumatol.200835581982518381790
     [Google Scholar]
  237. BarbhaiyaM. FeldmanC.H. ChenS.K. GuanH. FischerM.A. EverettB.M. Comparative risks of cardiovascular disease in systemic lupus erythematosus, diabetes and general medicaid patients.Arthritis Care Res.20207210143110.1002/acr.2432832475049
     [Google Scholar]
  238. ManziS. MeilahnE.N. RairieJ.E. ConteC.G. MedsgerT.A.Jr Jansen-McWilliamsL. D’AgostinoR.B. KullerL.H. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study.Am. J. Epidemiol.1997145540841510.1093/oxfordjournals.aje.a0091229048514
     [Google Scholar]
  239. FlottorpS FarahMG ThürmerH JohansenM FretheimA Non-pharmacological interventions to reduce the risk for cardiovascular disease: A summary of systematic reviews.Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH),Oslo, Norway2008
     [Google Scholar]
  240. DimaA. JurcutC. ChassetF. FeltenR. ArnaudL. Hydroxychloroquine in systemic lupus erythematosus: Overview of current knowledge.Ther. Adv. Musculoskelet. Dis.2022141759720X211073010.1177/1759720X21107300135186126
     [Google Scholar]
  241. SelzerF. Sutton-TyrrellK. FitzgeraldS. TracyR. KullerL. ManziS. Vascular stiffness in women with systemic lupus erythematosus.Hypertension20013741075108210.1161/01.HYP.37.4.107511304506
     [Google Scholar]
  242. Hippisley-CoxJ. CouplandC. BrindleP. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study.BMJ2017357j209910.1136/bmj.j209928536104
     [Google Scholar]
  243. BarinottiA. RadinM. CecchiI. FoddaiS.G. ArbrileM. RubiniE. MenegattiE. RoccatelloD. SciasciaS. Assessing the cardiovascular risk in patients with systemic lupus erythematosus: QRISK and GAPSS scores head-to-head.Int. J. Cardiol.202236318518910.1016/j.ijcard.2022.06.04035714714
     [Google Scholar]
  244. WangS-L. LiW. LiT-F. LiangX. YanY-L. LiuS-Y. QRISK3-based analysis of cardiovascular risk factors in patients with long-term but well-controlled systemic lupus erythematosus.Am. J. Transl. Res.20221453247326035702101
     [Google Scholar]
  245. MagderL.S. PetriM. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus.Am. J. Epidemiol.2012176870871910.1093/aje/kws13023024137
     [Google Scholar]
  246. GompelA. PietteJ.C. Systemic lupus erythematosus and hormone replacement therapy.Menopause Int.2007132657010.1258/17540450778079643317540136
     [Google Scholar]
  247. HaqueS. SkeochS. RakiehC. EdlinH. AhmadY. HoP. GorodkinR. AlexanderM.Y. BruceI.N. Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: The role of classic and SLE-related factors.Lupus Sci. Med.201851e00026710.1136/lupus‑2018‑00026730538814
     [Google Scholar]
  248. Hinojosa-AzaolaA. Romero-DiazJ. Vargas-RuizA.G. Nuñez-AlvarezC.A. Cicero-CasarrubiasA. Ocampo-TorresM.C. Sanchez-GuerreroJ. Venous and arterial thrombotic events in systemic lupus erythematosus.J. Rheumatol.201643357658610.3899/jrheum.15050626773122
     [Google Scholar]
  249. DrososG.C. VedderD. HoubenE. BoekelL. AtzeniF. BadrehS. BoumpasD.T. BrodinN. BruceI.N. González-GayM.Á. JacobsenS. KerekesG. MarchioriF. MukhtyarC. Ramos-CasalsM. SattarN. SchreiberK. SciasciaS. SvenungssonE. SzekaneczZ. TauscheA.K. TyndallA. van HalmV. VoskuylA. MacfarlaneG.J. WardM.M. NurmohamedM.T. TektonidouM.G. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.Ann. Rheum. Dis.202281676877910.1136/annrheumdis‑2021‑22173335110331
     [Google Scholar]
  250. TaylorE.B. RyanM.J. Understanding mechanisms of hypertension in systemic lupus erythematosus.Ther. Adv. Cardiovasc. Dis.2017111203210.1177/175394471663780726985016
     [Google Scholar]
  251. AlhabeebW. TashA.A. AlshamiriM. ArafatM. BalghithM.A. ALmasoodA. EltayebA. ElghetanyH. HassanT. AlshemmariO. National heart center/saudi heart association 2023 guidelines on the management of hypertension.J. Saudi Heart Assoc.2023351163910.37616/2212‑5043.132837020975
     [Google Scholar]
  252. LindholmL.H. PerssonM. AlaupovicP. CarlbergB. SvenssonA. SamuelssonO. Metabolic outcome during 1 year in newly detected hypertensives.J. Hypertens.20032181563157410.1097/00004872‑200308000‑0002212872052
     [Google Scholar]
  253. LithellH.O.L. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.Diabetes Care199114320320910.2337/diacare.14.3.2031828417
     [Google Scholar]
  254. MansiaG. De BackerG. DominiczakA. CifkovaR. FagardR. GermanoG. GrassiG. HeagertyA.M. KjeldsenS.E. LaurentS. NarkiewiczK. RuilopeL. RynkiewiczA. SchmiederR.E. Struijker BoudierH.A. ZanchettiA. European Society of Hypertension European Society of Cardiology 2007 ESH-ESC Guidelines for the management of arterial hypertension.Blood Press.200716313523210.1080/0803705070146108417846925
     [Google Scholar]
  255. WheltonP.K. CareyR.M. ManciaG. KreutzR. BundyJ.D. WilliamsB. Harmonization of the american college of cardiology/american heart association and european society of cardiology/european society of hypertension blood pressure/hypertension guidelines: Comparisons, reflections, and recommendations.Circulation20221461186887710.1161/CIRCULATIONAHA.121.05460235950927
     [Google Scholar]
  256. SenD. KeenR.W. Osteoporosis in systemic lupus erythematosus: Prevention and treatment.Lupus200110322723210.1191/09612030167141343911315358
     [Google Scholar]
  257. AlmehedK. Forsblad d’EliaH. KvistG. OhlssonC. CarlstenH. Prevalence and risk factors of osteoporosis in female SLE patients-extended report.Rheumatology20074671185119010.1093/rheumatology/kem10517500075
     [Google Scholar]
  258. ZhuT.Y. GriffithJ.F. AuS.K. TangX.L. KwokA.W. LeungP.C. LiE.K. TamL.S. Bone mineral density change in systemic lupus erythematosus: A 5-year followup study.J. Rheumatol.201441101990199710.3899/jrheum.13119024986848
     [Google Scholar]
  259. GraingeM.J. CouplandC.A.C. CliffeS.J. ChilversC.E.D. HoskingD.J. The Nottingham EPIC Study Group Cigarette smoking, alcohol and caffeine consumption, and bone mineral density in postmenopausal women.Osteoporos. Int.19988435536310.1007/s00198005007510024906
     [Google Scholar]
  260. KipenY. BrigantiE. StraussB. WillR. LittlejohnG. MorandE. Y K Three year followup of bone mineral density change in premenopausal women with systemic lupus erythematosus.J. Rheumatol.19992623103179972964
     [Google Scholar]
  261. TangB.M.P. EslickG.D. NowsonC. SmithC. BensoussanA. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis.Lancet2007370958865766610.1016/S0140‑6736(07)61342‑717720017
     [Google Scholar]
  262. CaetanoM. TerreriM.T. OrtizT. PinheiroM. SouzaF. SarniR. Bone mineral density reduction in adolescents with systemic erythematosus lupus: association with lack of vitamin D supplementation.Clin. Rheumatol.201534122065207010.1007/s10067‑015‑3011‑126227163
     [Google Scholar]
  263. AzzehF.S. Al-KushiA.G. HeaderE. ElSawyN. HijaziH. JazarA. GhaithM. AlarjahM. Effect of vitamin D and calcium supplementation in patients with systemic lupus erythematosus.Saudi J. Med. Med. Sci.20186313714210.4103/sjmms.sjmms_134_1730787840
     [Google Scholar]
  264. CraviotoM.C. Durand-CarbajalM. Jiménez-SantanaL. Lara-ReyesP. SeucA.H. Sánchez-GuerreroJ. Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: A randomized, double-blind, controlled trial.Arthritis Care Res.201163121654166310.1002/acr.2060822127965
     [Google Scholar]
  265. BuyonJ.P. PetriM.A. KimM.Y. KalunianK.C. GrossmanJ. HahnB.H. MerrillJ.T. SammaritanoL. LockshinM. AlarcónG.S. ManziS. BelmontH.M. AskanaseA.D. SiglerL. DooleyM.A. Von FeldtJ. McCuneW.J. FriedmanA. WachsJ. CroninM. Hearth-HolmesM. TanM. LicciardiF. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial.Ann. Intern. Med.200514212_Part_195396210.7326/0003‑4819‑142‑12_Part_1‑200506210‑0000415968009
     [Google Scholar]
  266. FernándezM. Calvo-AlénJ. BertoliA.M. BastianH.M. FesslerB.J. McGwinG.Jr ReveilleJ.D. ViláL.M. AlarcónG.S. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): Relationship between vascular events and the use of hormone replacement therapy in postmenopausal women.J. Clin. Rheumatol.200713526126510.1097/RHU.0b013e318156bbf517921793
     [Google Scholar]
  267. RossouwJ.E. AndersonG.L. PrenticeR.L. LaCroixA.Z. KooperbergC. StefanickM.L. JacksonR.D. BeresfordS.A. HowardB.V. JohnsonK.C. KotchenJ.M. OckeneJ. Writing Group for the Women’s Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial.JAMA2002288332133310.1001/jama.288.3.32112117397
     [Google Scholar]
  268. HumphriesK.H. GillS. Risks and benefits of hormone replacement therapy: The evidence speaks.CMAJ200316881001101012695385
     [Google Scholar]
  269. SinghB.K. SinghS. Systemic lupus erythematosus and infections.Reumatismo202072315416910.4081/reumatismo.2020.130333213128
     [Google Scholar]
  270. GargM. MuftiN. PalmoreT.N. HasniS.A. Recommendations and barriers to vaccination in systemic lupus erythematosus.Autoimmun Rev.201817109901001
     [Google Scholar]
  271. KhalifaM. KaabiaN. BahriF. Ben JaziaE. BouajinaE. OmezzineL.A. Infection in systemic lupus erythematosus.Med. Mal. Infect.2007371279279510.1016/j.medmal.2007.07.00317870271
     [Google Scholar]
  272. Diseases NCfI Respiratory. Shingles Zostavax Vaccination | What You Should Know.2020
     [Google Scholar]
  273. BassA.R. ChakravartyE. AklE.A. BinghamC.O. CalabreseL. CappelliL.C. JohnsonS.R. ImundoL.F. WinthropK.L. ArasaratnamR.J. BadenL.R. BerardR. BridgesS.L.Jr CheahJ.T.L. CurtisJ.R. FergusonP.J. HakkarinenI. OnelK.B. SchultzG. SivaramanV. SmithB.J. SparksJ.A. VogelT.P. WilliamsE.A. CalabreseC. CunhaJ.S. FontanarosaJ. Gillispie-TaylorM.C. GkrouzmanE. IyerP. LakinK.S. LeggeA. LoM.S. LockwoodM.M. SadunR.E. SinghN. SullivanN. TamH. TurgunbaevM. TurnerA.S. RestonJ. 2022 american college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases.Arthritis Rheumatol.202375333334810.1002/art.4238636597810
     [Google Scholar]
  274. AroraS. NikaA. SequeiraW. BlockJ.A. JollyM. Pneumococcal vaccination among lupus patients.J. Clin. Rheumatol.2021278e456e46110.1097/RHU.000000000000153632804752
     [Google Scholar]
  275. MastE.E. WeinbaumC.M. FioreA.E. AlterM.J. BellB.P. FinelliL. RodewaldL.E. DouglasJ.M.Jr JanssenR.S. WardJ.W. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC) A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of adults.MMWR Recomm. Rep.200655RR-1613317159833
     [Google Scholar]
  276. LiuH. DingQ. YangK. ZhangT. LiG. WuG. Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia.Rheumatology201150234334810.1093/rheumatology/keq30420929972
     [Google Scholar]
  277. TamL.S. ChanP.K.S. HoS.C. YuM.M. YimS.F. CheungT.H. WongM.C.S. LiE.K. Natural history of cervical papilloma virus infection in systemic lupus erythematosus - A prospective cohort study.J. Rheumatol.201037233034010.3899/jrheum.09064420032093
     [Google Scholar]
  278. NathR. MantC. LuxtonJ. HughesG. RajuK.S. ShepherdP. CasonJ. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients.Arthritis Care Res.200757461962510.1002/art.2266717471531
     [Google Scholar]
/content/journals/crr/10.2174/0115733971275638240429063041
Loading
Saudi National Clinical Practice Guidelines for Management of Adult Systemic Lupus Erythematosus
Curr. Rheumatol. Rev. 21, 70 (2025); https://doi.org/10.2174/0115733971275638240429063041
/content/journals/crr/10.2174/0115733971275638240429063041
/content/journals/crr/10.2174/0115733971275638240429063041
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): disease activity; guidelines; Saudi Arabia, Steroid-sparing agent, glucocorticoid; Systemic lupus erythematosus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test